The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis

被引:7
作者
Chen, Jing [1 ]
Hao, Qingfei [1 ]
Zhang, Jing [1 ]
Du, Yanna [1 ]
Chen, Haoming [1 ]
Cheng, Xiuyong [1 ]
机构
[1] Zhengzhou Univ, Dept Neonatol, Affiliated Hosp 1, Zhengzhou 450000, Peoples R China
关键词
Aflibercept; Bevacizumab; Conbercept; Laser; Retinopathy of prematurity; Ranibizumab; ZONE-II RETINOPATHY; INTRAVITREAL BEVACIZUMAB; TYPE-1; RETINOPATHY; REFRACTIVE OUTCOMES; PHOTOCOAGULATION; INJECTION; THERAPY; ERROR; RATES;
D O I
10.1186/s13052-023-01543-3
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background Retinopathy of prematurity (ROP) is typically treated with laser photocoagulation and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF). To the best of our knowledge, most systematic reviews have focused on comparing anti-VEGF against laser treatment while comparisons between different anti-VEGF agents are lacking. Thus, we conducted this meta-analysis to compare the efficacy and safety of different anti-VEGF agents or laser after primary ROP therapy.Methods We conducted a comprehensive search across multiple databases up to November 2022. We included studies that used anti-VEGF or laser for ROP with comparable cohorts.Results Overall, 44 studies were included in this meta-analysis. When comparing anti-VGEF with laser, we found that the anti-VEGF group had a significantly higher retreatment rate (RR = 1.56, 95%CI = [1.06, 2.31], p = 0.03), a longer time from treatment to retreatment (WMD = 5.99 weeks, 95%CI = [4.03, 7.95], p < 0.001), a lower retinal detachment rate (RR = 0.55, 95%CI = [0.30, 0.91], p = 0.02), higher spherical equivalent (WMD = 1.69D, 95%CI = [0.61, 2.77], p = 0.002), lower myopia rate (RR = 0.69, 95%CI = [0.50, 0.97], p = 0.03) and lower anisometropia rate (RR = 0.44, 95%CI = [0.29, 0.67], p = 0.0001). In comparisons between ranibizumab and bevacizumab, the intravitreal ranibizumab (IVR) group was associated with higher recurrence rate (RR = 2.02, 95%CI = [1.49, 2.73], p < 0.0001), higher retreatment rate (RR = 1.70, 95%CI = [1.17, 2.47], p = 0.0006), and lower high myopia rate (RR = 0.31, 95%CI = [0.12, 0.77], p = 0.01). Similarly, when compared to aflibercept and conbercept, the IVR cohort also demonstrated higher recurrence and retreatment rates. While no significant differences were observed in any of the variables included in the statistical analysis in the comparison between bevacizumab and aflibercept.Conclusions Anti-VEGF was associated with higher retreatment and lesser incidence of myopia as compared to laser. Laser therapy was linked to more complications like retinal detachment and myopia. Ranibizumab exhibited higher recurrence and retreatment rates compared to bevacizumab, aflibercept, and conbercept.
引用
收藏
页数:10
相关论文
共 63 条
[21]   Intravitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error Results [J].
Harder, Bjoern C. ;
Schlichtenbrede, Frank C. ;
von Baltz, Stefan ;
Jendritza, Waldemar ;
Jendritza, Bettina ;
Jonas, Jost B. .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2013, 155 (06) :1119-1124
[22]   Retinopathy of prematurity [J].
Hellstrom, Ann ;
Smith, Lois E. H. ;
Dammann, Olaf .
LANCET, 2013, 382 (9902) :1445-1457
[23]   Measuring inconsistency in meta-analyses [J].
Higgins, JPT ;
Thompson, SG ;
Deeks, JJ ;
Altman, DG .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7414) :557-560
[24]   Laser treatment for retinopathy of prematurity [J].
Houston, Samuel K. ;
Wykoff, Charles C. ;
Berrocal, Audina M. ;
Hess, Ditte J. ;
Murray, Timothy G. .
LASERS IN MEDICAL SCIENCE, 2013, 28 (02) :683-692
[25]   Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity A 5-Year Retrospective Analysis [J].
Hwang, Christopher K. ;
Hubbard, G. Baker ;
Hutchinson, Amy K. ;
Lambert, Scott R. .
OPHTHALMOLOGY, 2015, 122 (05) :1008-1015
[26]   Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser [J].
Isaac, Maram ;
Mireskandari, Kamiar ;
Tehrani, Nasrin .
JOURNAL OF AAPOS, 2015, 19 (02) :140-144
[27]   SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY [J].
Jin, Enzhong ;
Yin, Hong ;
Li, Xiaoxin ;
Zhao, Mingwei .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (08) :1595-1604
[28]   Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children [J].
Kabatas, Emrah Utku ;
Kurtul, Bengi Ece ;
Ozer, Pinar Altiaylik ;
Kabatas, Naciye .
CURRENT EYE RESEARCH, 2017, 42 (07) :1054-1058
[29]   Intravitreal ranibizumab versus laser photocoagulation for retinopathy of prematurity: efficacy, anatomical outcomes and safety [J].
Kang, Hyun Goo ;
Choi, Eun Young ;
Byeon, Suk Ho ;
Kim, Sung Soo ;
Koh, Hyoung Jun ;
Lee, Sung Chul ;
Kim, Min .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2019, 103 (09) :1332-1336
[30]  
Kang Hyun Goo, 2018, Korean J Ophthalmol, V32, P451, DOI 10.3341/kjo.2018.0011